Drug Discovery Hackathon 2020 by CSIR and AICTE
--Sharing is Caring--

Drug Discovery Hackathon 2020 by CSIR and AICTE
CSIR and AICTE launched an initiative to hold Drug Discovery Hackathon 2020 For COVID-19 disease

An initiative for potential drug discovery for Covid-19 disease has been launched by the All India Council for Technical Education (AICTE) and the Council of Scientific and Industrial Research (CSIR). The office of the Principal Scientific Advisor of the Government of India is supporting this Drug Discover Hackathon.

For both international and national participants, this hackathon will be open. This hackathon will be an online hackathon and all can access the generated data.

- Advertisement -

Any interested organization, startups, and CSIR labs will develop the potential ideas that emerge during the hackathon.

The Chief Innovation Officer, HRD Ministry, Dr. Abhay Jere shared information about the hackathon that the drug hackathon will be held on two themes:

  • Designing/optimization of new tools and algorithms
  • Drug design for anti-Covid-19 hit/lead molecule generation or re-purposing.

 

In the hackathon, researchers from all over the world including industry and academia experts can take part. Also, the students studying in India or abroad and holding Indian Passport can participate.

See Also
MIT Study - India Could See 2.87 Lakh COVID-19 Cases Per Day By Feb 2021

More details on the evaluation methodology, process, and the date will be announced soon. There will also be prizes awarded to the winners of the hackathon.

The organizing committee for the hackathon includes Dr. Abhay Jere; the Principal Scientific Advisor, Prof. K. VijayRaghavan; DG CSIR, Dr. Shekhar Mande; and AICTE Chairman, Prof. Anil Sahasrabudhe.

Source

Drug Discovery Hackathon 2020 For COVID-19 Launched by CSIR and AICTE, An initiative for potential drug discovery for Covid-19 disease has been launched by the All India Council for Technical Education (AICTE) and the Council of Scientific and Industrial Research (CSIR).

1 COMMENT

Comments are closed.